The role of toll-like receptors in peptic ulcer disease.
Shizhu JinNarayan NepalYang GaoPublished in: Immunological medicine (2021)
Helicobacter pylori (HP) is the primary etiologic factor that induces events in the immune system that lead to peptic ulcers. Toll-like receptors (TLRs) are an important part of the innate immune system, as they play pivotal roles in pathogen-associated molecular pattern (PAMP) recognition of HP as well host-associated damage-associated molecular patterns (DAMPs). Recent advancements such as COX-2 production, LPS recognition through TLR2, CagL, and CagY protein of HP activating TLR5, TLR9 activation via type IV secretion system (T4SS) using DNA transfer, TLR polymorphisms, their adaptor molecules, cytokines, and other factors play a significant role in PUD. Thus, some novel PUD treatments including Chuyou Yuyang granules, function by TLR4/NF-κB signaling pathway suppression and TNF-α and IL-18 inhibition also rely on TLR signaling. Similarly glycyrrhetinic acid (GA) treatment activates TLR-4 in Ana-1 cells not via TRIF, but via MYD88 expression, which is significantly upregulated to cure PUD. Therefore, understanding TLR signaling complexity and its resultant immune modulation after host-pathogen interactions is pivotal to drug and vaccine development for other diseases as well including cancer and recent pandemic COVID-19. In this review, we summarize the TLRs and HP interaction; its pathophysiology-related signaling pathways, polymorphisms, and pharmaceutical approaches toward PUD.
Keyphrases
- toll like receptor
- inflammatory response
- immune response
- signaling pathway
- helicobacter pylori
- nuclear factor
- coronavirus disease
- induced apoptosis
- sars cov
- lps induced
- pi k akt
- oxidative stress
- rheumatoid arthritis
- epithelial mesenchymal transition
- poor prognosis
- cell cycle arrest
- single molecule
- helicobacter pylori infection
- cell proliferation
- papillary thyroid
- emergency department
- pet ct
- young adults
- binding protein
- long non coding rna
- electronic health record
- adverse drug
- protein protein
- circulating tumor cells